W
Walden Biosciences
Biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease
About Walden Biosciences
Walden Biosciences is a biotech startup that operates in the healthcare sector, specifically focusing on the treatment of kidney diseases. The company's mission is to transform the treatment landscape of chronic kidney disease (CKD) and acute kidney injury (AKI). CKD is a condition where the kidneys are progressively damaged and fail over time, while AKI is a rapid loss of kidney function in a short period.
The company's target market is vast, with over 850 million people worldwide suffering from some form of kidney disease. In the US alone, there are 37 million patients with CKD. This number is significantly higher than the number of people suffering from cancer, HIV/AIDS, or diabetes.
Walden Biosciences' business model revolves around the development and commercialization of innovative treatments for kidney diseases. The company generates revenue by conducting clinical trials and eventually selling the developed drugs. Recently, they announced the first subject dosed in their first-in-humans Phase 1 Clinical Trial of WAL0921, a drug in development for the treatment of chronic kidney diseases.
The company also hosts virtual events to educate and engage with the public and potential investors about their work and the importance of their mission. The next event, titled "Transforming the Treatment Landscape of Chronic Kidney Disease," is scheduled for November 14, 2023.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 79.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2023 | $0 | — | ATEM Capital | — |
| SERIES AOther financing | Oct 2020 | $51M | $204M | ARCH Venture Partners · UCB Ventures | — |
Growth signals
Latest recorded traffic for Walden Biosciences is 700 monthly website visits, down 18.6% over the last three months. Walden Biosciences's team grew 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Walden Biosciences in the Cambridge ecosystem
The Walden Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
ARCH Venture Partners
UCB Ventures
ATEM Capital
Other known investors2 additional known investors
Harvard University
Rush University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Walden Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Walden Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









